Все публикации

Analyzing the BM

Analyzing the BM immune microenvironment in RAS/RAF-mutated myeloma treated with a MEK inhibitor

Mechanical forces in

Mechanical forces in the CLL microenvironment and the importance of modeling them in vitro

Managing AEs associated

Managing AEs associated with bortezomib in the treatment of Waldenström's macroglobulinemia

Adverse events associated

Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia

The advancements and

The advancements and remaining challenges in precision medicine for CLL

The GEM-OPTIMAL study:

The GEM-OPTIMAL study: an observational study using ALCYONE-optimized real-world evidence data

The evolution of

The evolution of BCL2 inhibition in CLL

Overcoming challenges with

Overcoming challenges with targeted therapies for CLL: high-risk mutations and BTKi resistance

Changing attitudes to

Changing attitudes to using interferon in pediatric patients with MPNs

The impact of

The impact of SETD2 loss on CML progression

The prognostic value

The prognostic value of MRD and PB versus BM measurements in T-ALL

Diagnosing MDS/MPN overlap

Diagnosing MDS/MPN overlap syndromes: challenges that remain

Contemporary challenges in

Contemporary challenges in polycythemia vera management

Is there a

Is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for MCL?

Development and evaluation

Development and evaluation of a novel CAR-T cell therapy against CALR mutant neoplasms

Incorporating new technologies

Incorporating new technologies into the real-life classification of AML to guide treatment decisions

The sensitization of

The sensitization of immune checkpoint inhibitors with subsequent chemotherapy in R/R HL

Insights into the

Insights into the influence of cardiovascular toxicity risk on treatment selection in CLL

Insights into the

Insights into the future of the CLL treatment landscape

Patients with CLL

Patients with CLL on continuous ibrutinib have a life expectancy comparable to healthy individuals

Proteome dynamics during

Proteome dynamics during normal and malignant hematopoietic stem cell expansion

Selecting between BTK

Selecting between BTK inhibitors in MCL & addressing resistance to these agents

Insights into the

Insights into the real-world evidence for C3 inhibition in the treatment of PNH

The STARGLO trial:

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCL